Drugs Containing Excipient (Inactive Ingredient) PEG-60 HYDROGENATED CASTOR OIL

« Back to Dashboard

Generic drugs containing PEG-60 HYDROGENATED CASTOR OIL excipient

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	lidocaine and prilocaine	0121-1002	PEG-60 HYDROGENATED CASTOR OIL
Padagis US LLC	lidocaine and prilocaine	0574-2042	PEG-60 HYDROGENATED CASTOR OIL
MAJOR Pharmaceuticals	lidocaine and prilocaine	0904-6989	PEG-60 HYDROGENATED CASTOR OIL

PEG-60 Hydrogenated Castor Oil Market Dynamics, Financial Trajectory, and Pharmaceutical Supply Chain

Last updated: October 22, 2026

PEG-60 hydrogenated castor oil is a nonionic pharmaceutical surfactant and solubilizer used primarily in oral, topical, and selected parenteral formulations. Its market outlook is stable to moderately positive, driven by poorly water-soluble drug development, reformulation activity, and demand for excipients with established pharmacopeial and regulatory histories. Public companies do not report PEG-60 hydrogenated castor oil revenue separately, so financial analysis must rely on excipient segment performance, formulation demand, manufacturing capacity, and pricing structure rather than a verified standalone market size.

The product is generally known in pharmacopeial terminology as polyoxyl 60 hydrogenated castor oil. It is sold through specialty excipient portfolios under grades such as Kolliphor RH 60 and comparable supplier-specific brands. Its competitive position depends on regulatory documentation, batch consistency, residual impurity control, global supply reliability, and compatibility with the active pharmaceutical ingredient.

What is PEG-60 hydrogenated castor oil used for in pharmaceuticals?

PEG-60 hydrogenated castor oil is an ethoxylated derivative of hydrogenated castor oil. The material combines a hydrophobic castor-oil-derived component with polyethylene glycol chains, allowing it to reduce interfacial tension and improve the apparent solubility or dispersion of hydrophobic drug substances.

Attribute	Description
Common name	PEG-60 hydrogenated castor oil
Pharmacopeial name	Polyoxyl 60 hydrogenated castor oil
Functional class	Nonionic surfactant, solubilizer, emulsifier
Typical formulation role	Solubilization, wetting, emulsification, dispersion stabilization
Primary dosage forms	Oral liquids, soft and hard capsules, topical products, selected parenteral systems
Feedstock	Hydrogenated castor oil and ethylene oxide
Key quality concerns	Ethoxylation profile, free polyethylene glycol, residual reactants, peroxide value, water content, heavy metals, microbial quality
Regulatory position	Pharmaceutical excipient subject to compendial and product-specific review

The material is not the active pharmaceutical ingredient. It has no therapeutic mechanism and does not receive independent drug approval. Its regulatory acceptability is assessed through the finished dosage form, the applicable pharmacopeial monograph, and the sponsor’s excipient qualification package.

Which pharmaceutical formulations use PEG-60 hydrogenated castor oil?

PEG-60 hydrogenated castor oil is most valuable where a formulation requires a liquid or semisolid solubilizer for a lipophilic active ingredient.

Oral formulations

Oral liquids and concentrated solutions are important applications because poorly soluble active ingredients can precipitate after dilution or during storage. PEG-60 hydrogenated castor oil can improve wetting and help maintain a clear or uniform formulation.

Potential oral uses include:

• Oral drops and solutions
• Syrups and concentrated liquid medicines
• Soft-gel and liquid-filled capsules
• Nutraceutical and veterinary formulations
• Drug products requiring taste-masking or dispersion stabilization

The principal commercial limitation is dose-dependent excipient exposure. The amount required for solubilization can become substantial when the active ingredient has very low aqueous solubility.

Topical and dermal formulations

The material can function as a solubilizer or emulsifying aid in creams, lotions, gels, and other semisolid systems. Demand is linked to dermatology products containing oils, fragrances, preservatives, vitamins, and poorly soluble actives.

Topical use is sensitive to:

• Skin irritation potential
• Residual ethylene oxide and related impurities
• Odor and color
• Compatibility with preservatives
• Consumer preference for non-ethoxylated or naturally positioned ingredients

Parenteral formulations

Hydrogenated castor oil-based polyoxyl surfactants have a history in solubilizing hydrophobic compounds for injectable delivery. Parenteral applications impose the strictest quality requirements and require detailed toxicological and impurity control.

For injectable products, suppliers must support:

• Endotoxin control
• Low bioburden manufacturing
• Sterility or sterile filtration compatibility
• Extractables and leachables assessment
• Container-closure compatibility
• Tight control of oxidation and degradation products

Parenteral use can generate higher value per kilogram than oral or topical use, but qualification cycles are longer and supplier switching is difficult.

How large is the PEG-60 hydrogenated castor oil market?

No major public pharmaceutical manufacturer reports PEG-60 hydrogenated castor oil revenue as a standalone line item. Available market reports typically group it with polyoxyl castor oils, pharmaceutical surfactants, solubilizers, or broader specialty excipients. Those aggregated figures cannot be used as a verified PEG-60 hydrogenated castor oil market size.

The market is best assessed through four demand pools:

1. New formulations containing poorly soluble small molecules.
2. Reformulation of liquid, topical, and injectable products.
3. Generic drug development requiring an established solubilization platform.
4. Nutraceutical, veterinary, and personal-care applications that compete for related manufacturing capacity.

Pharmaceutical demand has a higher technical value but lower volume than cosmetic or industrial demand. A pharmaceutical-grade supplier can command a premium because customers purchase regulatory support, documentation, and supply continuity rather than only the chemical material.

What is driving demand for PEG-60 hydrogenated castor oil?

Poor aqueous solubility among drug candidates

Low aqueous solubility remains a common development problem, particularly for oral small molecules. Surfactants and cosolvents are used to improve dissolution, absorption, and formulation stability. PEG-60 hydrogenated castor oil competes with polysorbates, poloxamers, PEGs, glycerides, cyclodextrins, lipid excipients, and solvent systems.

Growth in liquid and enabling formulations

Liquid formulations can support pediatric, geriatric, veterinary, and swallowing-impaired populations. They also provide a route for APIs that are difficult to compress or encapsulate. PEG-60 hydrogenated castor oil is positioned for products that require a relatively robust solubilization system without relying exclusively on high levels of ethanol or propylene glycol.

Generic and hybrid drug development

Generic applicants can select a formulation platform with an established excipient history. This reduces development risk, although it does not eliminate the need to demonstrate bioequivalence, impurity control, and finished-product stability.

Reformulation and supply-chain diversification

Drug manufacturers increasingly qualify secondary excipient sources for critical products. The opportunity is strongest where the excipient is used in a registered commercial product and the original supplier has long lead times, limited regional production, or narrow capacity.

How does PEG-60 hydrogenated castor oil compare with competing pharmaceutical surfactants?

Excipient	Principal advantage	Principal limitation	Competitive relationship
PEG-60 hydrogenated castor oil	Strong solubilization and established nonionic surfactant chemistry	Impurity and tolerability scrutiny; limited supplier base	Direct competitor to PEGylated castor-oil grades
PEG-40 hydrogenated castor oil	Broad use and established formulation history	Different hydrophilic-lipophilic balance and performance profile	Close substitute where the formulation tolerates grade changes
Polysorbate 20 or 80	Extensive regulatory and commercial use	Oxidation, hydrolysis, peroxide formation, and lot variability	Major substitute in biologics and aqueous formulations
Poloxamer 188 or 407	Strong wetting and stabilization properties	May not provide equivalent solubilization	Substitute in selected oral, injectable, and biologic formulations
PEG 400	Low cost and broad availability	Often requires cosolvent combinations; toxicity limits at high exposure	Complementary rather than direct substitute
Medium-chain triglycerides and glycerides	Useful for lipid-based delivery	More complex processing and dispersion behavior	Substitute in oral lipid formulations
Cyclodextrins	Powerful complexation for selected APIs	Cost, dose burden, and regulatory constraints	High-value alternative for specific molecules

A formulation cannot automatically substitute PEG-60 hydrogenated castor oil with PEG-40 hydrogenated castor oil or a polysorbate. The change can alter solubility, particle size, release, absorption, viscosity, preservative performance, and stability. A supplier change within the same grade may require less development work than a change to a different surfactant class, but both can trigger regulatory comparability requirements.

Which companies supply PEG-60 hydrogenated castor oil?

The competitive field includes global specialty chemical manufacturers, pharmaceutical excipient specialists, and regional producers of ethoxylated castor-oil derivatives.

BASF is a prominent supplier of pharmaceutical solubilizers and surfactants under the Kolliphor portfolio. Its excipient business is supported by global quality systems, regulatory documentation, and broad formulation-development resources. BASF identifies hydrogenated castor oil derivatives as solubilizers used in pharmaceutical formulations (BASF, n.d.-a).

Other competition comes from:

• Croda and its pharmaceutical excipient operations
• Nikko Chemicals and related Japanese specialty-chemical suppliers
• Gattefossé, particularly in lipid and formulation excipients
• Regional Asian manufacturers supplying polyoxyl castor-oil grades
• Contract manufacturers producing customer-specific or private-label excipient grades

The relevant competitive advantage is not only manufacturing cost. Pharmaceutical customers evaluate supplier qualification, change-control practices, audit history, pharmacopeial compliance, regional inventory, technical support, and the ability to provide consistent impurity profiles.

What is the financial trajectory for PEG-60 hydrogenated castor oil?

The financial trajectory is likely to be steady rather than high-growth. The product is a specialty excipient with recurring demand from approved products, but its growth is constrained by substitution and limited standalone market visibility.

Financial driver	Directional impact
New poorly soluble drug launches	Positive
Generic formulation activity	Positive
Injectable product qualification	Positive but slow
Raw material cost for castor oil	Variable
Ethylene oxide and energy costs	Negative during inflationary periods
Supplier qualification barriers	Positive for incumbent margins
Substitution by polysorbates or poloxamers	Negative
Cosmetic and industrial competition for capacity	Mixed
Regional manufacturing expansion	Potentially negative for pricing
Regulatory impurity scrutiny	Negative for low-quality suppliers, positive for qualified suppliers

Pricing structure

Pharmaceutical-grade PEG-60 hydrogenated castor oil is priced above industrial material because the price includes:

• GMP manufacturing controls
• Compendial testing
• Batch documentation
• Regulatory support
• Stability data
• Audits and quality agreements
• Change-notification obligations
• Regional warehousing and technical service

High-volume oral applications are more price-sensitive. Parenteral applications can support stronger pricing because switching suppliers requires extensive qualification and may affect regulatory filings.

Margin outlook

Incumbent suppliers with validated pharmaceutical production and regulatory files are positioned to defend margins better than commodity producers. Margin pressure is most likely in standard oral and topical applications where buyers can qualify multiple sources.

Margin support is strongest when:

• The excipient is embedded in an approved formulation.
• The supplier has a drug master file or comparable regulatory package.
• The customer uses the excipient in a sterile or high-risk dosage form.
• The product requires a narrow and reproducible ethoxylation profile.
• A second source is not readily available in the customer’s region.

What FDA and pharmacopeial status applies to PEG-60 hydrogenated castor oil?

PEG-60 hydrogenated castor oil is not approved as an independent drug. Its regulatory status comes from its use as an excipient in specific drug products.

The FDA Inactive Ingredient Database is the primary public reference for prior use of excipients in approved drug products. The relevant entry may appear under polyoxyl 60 hydrogenated castor oil or a related nomenclature rather than the commercial name PEG-60 hydrogenated castor oil (U.S. Food and Drug Administration, n.d.-a).

Key regulatory points include:

• The finished drug application must identify the excipient and its quantity.
• The sponsor must demonstrate suitability for the dosage form and route.
• The supplier must control residual reactants and degradation products.
• Parenteral use requires more extensive safety and quality evidence.
• A compendial monograph can support identity and quality testing but does not replace product-specific approval.
• The FDA does not grant an Orange Book exclusivity period to the excipient itself.

The United States Pharmacopeia and National Formulary contains monograph-based standards for polyoxyl hydrogenated castor oil materials. European and other national pharmacopoeias may use related terminology and specifications. Supplier grades should be mapped carefully because similar trade names can represent different ethoxylation levels and quality specifications.

What patents protect PEG-60 hydrogenated castor oil?

The base excipient is a mature chemical material. Patent protection for the underlying composition is unlikely to be the primary commercial barrier. The material’s commercial protection comes from manufacturing know-how, process control, quality data, customer qualification, and regulatory documentation.

Relevant IP categories include:

• Ethoxylation process controls
• Purification methods
• Low-peroxide or low-impurity grades
• Specific pharmaceutical compositions
• Drug-delivery systems using the excipient
• Combination formulations with poorly soluble APIs
• Sterile or low-endotoxin manufacturing processes

A patent covering a drug formulation that contains PEG-60 hydrogenated castor oil can remain relevant even when the excipient itself is off-patent. Such patents may cover a specific concentration range, API-to-excipient ratio, dosage form, release profile, or method of treatment.

Does PEG-60 hydrogenated castor oil have Orange Book or Paragraph IV risk?

PEG-60 hydrogenated castor oil itself has no Orange Book listing because it is an inactive ingredient, not an approved active drug product. It therefore has no independent Orange Book expiration date, regulatory exclusivity period, or Paragraph IV challenge pathway.

Paragraph IV risk arises only when the excipient is used in a finished drug that has listed patents. A generic applicant may challenge formulation, method-of-use, or drug-product patents covering a product that contains PEG-60 hydrogenated castor oil. The challenge would target the finished drug’s listed patents, not the excipient’s chemical identity.

Are biosimilar risks relevant to PEG-60 hydrogenated castor oil?

Biosimilar risk is relevant only indirectly. Biologic manufacturers may use nonionic surfactants to limit aggregation and interfacial stress, but polysorbates and poloxamers are more established in many biologic formulations. A biosimilar sponsor may retain the reference product’s excipient system or select an alternative after comparability testing.

PEG-60 hydrogenated castor oil can benefit from biologic formulation demand where it demonstrates acceptable stability and tolerability. It also faces substitution risk if a sponsor standardizes on polysorbate 20, polysorbate 80, poloxamer 188, or another surfactant across its biologics portfolio.

What manufacturing and IP barriers affect supply?

The principal barriers are operational rather than patent-based.

Raw materials

Hydrogenated castor oil quality depends on the source and processing of castor oil. Ethylene oxide handling creates significant safety, environmental, and regulatory requirements. Energy consumption and plant utilization influence cost.

Process consistency

Ethoxylation produces a distribution of polyethylene glycol chain lengths rather than a single molecular species. Suppliers must control the distribution and associated impurities. Batch-to-batch variation can change hydrophilic-lipophilic balance and formulation performance.

Regulatory qualification

A pharmaceutical customer may spend months or years qualifying a new source, depending on the dosage form and regulatory filing. This creates switching costs and protects established suppliers.

Regional supply

Manufacturing concentration in Europe and Asia creates exposure to freight costs, port disruption, export restrictions, and regional inventory shortages. Local or dual-source supply can command a premium even when the chemical grade is widely available.

What generic launch scenarios affect PEG-60 hydrogenated castor oil demand?

Three scenarios are commercially relevant:

1. In a standard oral product, a generic entrant may use the same excipient or a lower-cost substitute. Volume rises, but price pressure is high.
2. In a complex liquid or injectable product, the generic entrant may retain the excipient because formulation performance and regulatory risk favor continuity. This supports supplier value.
3. In a reformulated product, the sponsor may replace PEG-60 hydrogenated castor oil with a polysorbate, poloxamer, glyceride, or cyclodextrin. The incumbent supplier loses volume but the broader solubilizer market remains active.

How strong is the commercial position of PEG-60 hydrogenated castor oil?

The product has a medium-strength commercial position.

Its strengths are established excipient chemistry, broad formulation utility, recurring demand, and qualification barriers in regulated products. Its weaknesses are limited public market transparency, substitution by other surfactants, exposure to raw-material costs, and route-specific tolerability constraints.

The strongest business case is a pharmaceutical-grade supplier with global distribution, validated manufacturing, and technical support for difficult-to-solubilize APIs. The weakest position is an undifferentiated supplier competing only on price in oral or cosmetic applications.

Key Takeaways

• PEG-60 hydrogenated castor oil is a mature, specialty pharmaceutical surfactant and solubilizer.
• Demand is linked to poorly soluble drugs, liquid formulations, topical products, generic development, and selected injectable systems.
• Public companies do not disclose standalone PEG-60 hydrogenated castor oil revenue.
• Financial growth is likely steady, with better pricing power in sterile and technically complex formulations.
• BASF and other specialty excipient suppliers compete through quality systems, regulatory support, and supply reliability.
• The excipient itself has little direct patent protection or Orange Book relevance.
• Finished-product formulation patents can create indirect Paragraph IV exposure.
• The main risks are substitution, impurity scrutiny, raw-material inflation, and concentrated supply.
• Supplier qualification and formulation switching costs provide the strongest commercial protection.
• The market is more defensible as a regulated pharmaceutical grade than as a commodity surfactant.

FAQs

Is PEG-60 hydrogenated castor oil the same as PEG-40 hydrogenated castor oil?

No. The two materials have different average ethoxylation levels and can produce different solubilization, viscosity, stability, and tolerability profiles. They should not be treated as automatically interchangeable.

Is PEG-60 hydrogenated castor oil suitable for injectable drugs?

It can be used in selected parenteral formulations, subject to product-specific toxicology, endotoxin, bioburden, impurity, and compatibility requirements. Injectable use requires a higher quality and regulatory standard than topical or oral use.

Can a pharmaceutical company change suppliers without changing its formulation?

A change within the same qualified grade may be manageable, but the sponsor must assess equivalence, impurity profiles, stability, manufacturing changes, and regulatory obligations. The change may require notification or approval depending on the product and jurisdiction.

Does PEG-60 hydrogenated castor oil increase drug absorption?

It can improve apparent solubility, wetting, dispersion, and sometimes dissolution. Any effect on absorption depends on the API, concentration, dosage form, gastrointestinal conditions, and the complete formulation.

Is PEG-60 hydrogenated castor oil a high-growth pharmaceutical ingredient?

It is more accurately characterized as a stable specialty excipient with selective growth opportunities. Expansion depends on new poorly soluble drugs, complex generics, liquid formulations, and higher-value sterile applications rather than rapid volume growth across all pharmaceutical segments.

References

1. BASF. (n.d.-a). Kolliphor pharmaceutical excipients. BASF SE. https://pharma.basf.com
2. BASF. (n.d.-b). Kolliphor RH 60 pharmaceutical excipient information. BASF SE. https://pharma.basf.com
3. European Medicines Agency. (2017). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu
4. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. U.S. Food and Drug Administration. (n.d.-b). Drug Master Files guidance and regulatory information. https://www.fda.gov
6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Polyoxyl 60 hydrogenated castor oil monograph. USP-NF.
7. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu
8. BASF SE. (2024). Annual report 2023. https://www.basf.com/global/en/investors.html